Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan.

Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Chen JW.

BMC Cardiovasc Disord. 2017 Jan 28;17(1):42. doi: 10.1186/s12872-017-0471-z.

2.

Pleiotropic Effects of Statins on the Cardiovascular System.

Oesterle A, Laufs U, Liao JK.

Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537. Review.

PMID:
28057795
3.

Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.

Lee SY, Oh SJ, Kim EJ, Oum CY, Park SH, Oh J, Kim JS, Kim BK, Park S, Chang HJ, Hong GR, Ko YG, Kang SM, Choi D, Ha JW, Hong MK, Jang Y, Chung N, Lee SH.

PLoS One. 2016 Nov 8;11(11):e0166246. doi: 10.1371/journal.pone.0166246. eCollection 2016.

4.

Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials.

Liu HW, Bian SY, Zhu QW, Zhao YX.

J Geriatr Cardiol. 2016 Aug;13(8):693-700.

5.

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.

Sasso FC, Lascar N, Ascione A, Carbonara O, De Nicola L, Minutolo R, Salvatore T, Rizzo MR, Cirillo P, Paolisso G, Marfella R; NID-2 study group.

Cardiovasc Diabetol. 2016 Oct 13;15(1):147.

6.

The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis.

Tan P, Wei S, Yang L, Tang Z, Cao D, Liu L, Lei J, Fan Y, Gao L, Wei Q.

Sci Rep. 2016 Jul 7;6:29106. doi: 10.1038/srep29106.

7.

All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

De Caterina R, Salvatore T, Marchioli R.

Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.

8.

LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.

Tan P, Wei S, Tang Z, Gao L, Zhang C, Nie P, Yang L, Wei Q.

Sci Rep. 2016 Apr 14;6:24521. doi: 10.1038/srep24521.

9.

Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis.

Sun H, Yuan Y, Wang P, Cai R, Xia W, Huang R, Wang S.

Lipids Health Dis. 2015 Nov 2;14:140. doi: 10.1186/s12944-015-0147-6.

10.

Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.

Iwere RB, Hewitt J.

Br J Clin Pharmacol. 2015 Sep;80(3):363-71. doi: 10.1111/bcp.12687. Epub 2015 Jul 22. Review.

11.

Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis.

Cai H, Zhang G, Wang Z, Luo Z, Zhou X.

PLoS One. 2015 Jun 1;10(6):e0126944. doi: 10.1371/journal.pone.0126944. eCollection 2015. Review.

12.

Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.

Hermans MP, Bouenizabila E, Amoussou-Guenou DK, Ahn SA, Rousseau MF.

Cardiovasc Diabetol. 2015 May 21;14:60. doi: 10.1186/s12933-015-0226-z.

13.

Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia.

Zhao J, Yan HM, Li Y, Wang J, Han L, Wang ZH, Tang MX, Zhang W, Zhang Y, Zhong M.

J Zhejiang Univ Sci B. 2015 May;16(5):380-7. doi: 10.1631/jzus.B1400181.

14.

Statins can delay insulin use and reduce diabetes-related diseases in Asian patients with type 2 diabetes.

Chen HH, Yeh CJ, Lin CL, Yeh SY, Kao CH.

Medicine (Baltimore). 2015 May;94(17):e735. doi: 10.1097/MD.0000000000000735.

15.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ.

Eur Heart J. 2015 Jun 21;36(24):1536-46. doi: 10.1093/eurheartj/ehv072. Epub 2015 Mar 23. Review.

16.

Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands.

Chaplin S, Scuffham PA, Alon M, van den Boom G.

Neth Heart J. 2004 Aug;12(7-8):331-336.

17.

Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study.

Walker EJ, Ko AH, Holly EA, Bracci PM.

Cancer. 2015 Apr 15;121(8):1287-94. doi: 10.1002/cncr.29256. Epub 2015 Feb 3.

18.

Statins: definitive translational research.

Grundy SM.

Mol Med. 2014 Dec 16;20 Suppl 1:S20-3. doi: 10.2119/molmed.2014.00194. Review. No abstract available.

19.

Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.

de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E.

PLoS One. 2014 Nov 5;9(11):e111247. doi: 10.1371/journal.pone.0111247. eCollection 2014.

20.

Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL.

Hepatology. 2014 Aug;60(2):679-86. doi: 10.1002/hep.27157. Epub 2014 May 13.

Supplemental Content

Support Center